advertisement
11.3.3 Apraclonidine, brimonidine (8)
Showing records 1 to 8
Display all abstracts in classification 11.3.3 Apraclonidine, brimonidine
Search within classification 11.3.3 Apraclonidine, brimonidine10421 Randomized controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure
Aung T; Oen FT; Wong HT; Chan YH; Khoo BK; Liu YP; Ho CL; See J; Thean LH; Viswanathan AC
British Journal of Ophthalmology 2004; 88: 88-94
10121 Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children
Bowman RJ; Cope J; Nischal KK
Eye 2004; 18: 24-26
10123 Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
Journal of Glaucoma 2004; 13: 163-167
10124 Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures
Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F
Journal of Glaucoma 2004; 13: 149-157
10128 The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmologica Scandinavica 2004; 82: 161-165
10126 Aqueous humor flow in normal human eyes treated with brimonidine and dorzolamide, alone and in combination
Tsukamoto H; Larsson LI
Archives of Ophthalmology 2004; 122: 190-193
10122 Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
Journal of Glaucoma 2004; 13: 168-173
10486 Evaluation of the comfort of Alphagan® P compared with Alphagan® in irritated eyes
Mundorf T; Wilcox KA; Ousler III GW; Welch D; Abelson MB
Advances in Therapy 2003; 20: 329-336
